close

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and primary care physicians primarily in the United States. The company markets Testim, a topical 1% testosterone gel for the treatment of hypogonadism. Its product pipeline also includes XIAFLEX, an injectable collagenase enzyme, which is in Phase III of development for the treatment of Dupuytren's contracture; and in Phase II of development for the treatment of Peyronie's Disease and Adhesive Capsulitis. The company's product pipeline also comprises AA4010, which is in Phase I of development for the treatment of overactive bladder using its transmucosal film delivery system; and A Fentanyl, a pain product, which is in Phase I of development. It has agreement with Pfizer, Inc. for the development, commercialization, and supply of XIAFLEX in European and Eurasian countries. The company was founded in 1999 and is headquartered in Malvern, Pennsylvania.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	19.45
Volume	181327
Volume Avg	438187
52 Week High	24.88
52 Week Low	13.59
PE	N/A
PE (group average)	39
EPS Year	-0.69
EPS change Q/Q	-26.47%
EPS change Q/Q Yr ago	-38.89%
EPS change Q/Q next Q est	-150%
EPS change Y/Y	-3.51%
REV change Q/Q	-5.5%
REV change Q/Q Yr ago	28.35%
EPS next Q est	-0.10
EPS next Y est	0.19
Divident Annual	0.00
Dividend Yield	0%